M
MedPayIQ
CPT 93025Cardiology

Microvolt t-wave assess

CPT 93025 covers microvolt T-wave alternans (MTWA) testing, a specialized heart rhythm analysis that detects tiny changes in the electrical signal of the heart that may predict sudden cardiac death risk. This non-invasive test helps doctors assess whether patients with heart disease are at high risk for life-threatening arrhythmias.

Showing rates for
National Average

RVU breakdown

Work RVU
0.75
PE RVU (NF)
3.04
MP RVU
0.04
Total RVU
3.83

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

Billing tips

  1. Verify Medicare LCD coverage criteria before scheduling MTWA testing, as many contractors have specific coverage limitations regarding ejection fraction thresholds, prior testing requirements, and approved indications

    Impact: Prevents denials; uncovered tests result in $0 reimbursement and require ABN for patient billing

  2. Document whether test result was positive, negative, or indeterminate with specific MTWA voltage values and interpretation methodology, as indeterminate results may not support medical necessity for repeat testing

    Impact: Indeterminate results without clear documentation may trigger recoupment of the full $123.89 payment

  3. Do not bill 93025 on the same date as routine ECG interpretation (93000-93010) without modifier 59 and clear documentation of separate medical necessity, as these may bundle

    Impact: Improper bundling results in denial of 93025 ($123.89 loss) or potential fraud investigation

  4. Ensure the physician interpretation includes assessment of cardiac rhythm stability during testing, any artifacts or technical limitations, and explicit risk stratification conclusion for sudden cardiac death

    Impact: Incomplete interpretations are primary audit target; may result in downcoding or full denial

  5. Bill globally (no modifier) only when your practice owns the MTWA equipment and provides both technical performance and physician interpretation; split billing with 26/TC when services are divided

    Impact: Incorrect component billing can result in overpayment recovery or underpayment of 40-60% of allowed amount

  6. Maintain manufacturer-specific MTWA equipment calibration and quality control logs as part of technical documentation, particularly for Medicare and commercial audits

    Impact: Lack of quality control documentation can result in technical component denial or practice-wide audit expansion

Common denials

Medical necessity denial due to lack of documented structural heart disease, reduced ejection fraction, or other qualifying cardiac condition per LCD requirements

How to appeal: Submit appeal with echocardiogram report showing reduced LVEF, cardiac catheterization results, prior MI documentation, or cardiomyopathy diagnosis. Include specific LCD reference showing patient meets coverage criteria. Provide ordering physician's rationale for sudden cardiac death risk stratification and how results influenced treatment planning.

Duplicate service denial when billed on same date as other cardiac diagnostic testing such as stress testing, Holter monitoring, or event recording without appropriate modifier

How to appeal: Resubmit claim with modifier 59 or XU demonstrating distinct procedural service. Provide documentation showing MTWA was performed for separate clinical indication from other cardiac testing, used different methodology, and provided unique clinical information not obtainable from concurrent tests. Include start/stop times showing separate procedures.

Insufficient documentation denial when physician interpretation lacks specific MTWA voltage measurements, test methodology description, or clear clinical correlation

How to appeal: Submit complete MTWA report including microvolt measurements, heart rate achieved during testing, presence/absence of T-wave alternans with specific voltage values, interpretation of positive/negative/indeterminate result, and clinical recommendation regarding arrhythmia risk. Ensure report is signed and dated by interpreting physician with credentials documented.

Non-covered service denial based on LCD exclusions such as testing performed too frequently, patient not meeting ejection fraction threshold, or MTWA used for non-approved indication

How to appeal: If patient truly meets coverage criteria, submit appeal with specific LCD citation and supporting documentation. If LCD genuinely excludes the service, appeal is unlikely to succeed; consider requesting LCD reconsideration or billing patient directly with properly executed ABN. Provide peer-reviewed literature supporting clinical utility if challenging LCD criteria.

Frequently asked questions

What is the Medicare reimbursement rate for CPT 93025 in 2025?

The 2025 Medicare national average reimbursement for CPT 93025 is $123.89 for both facility and non-facility settings. This rate is based on 3.83 total RVUs (0.75 work RVU, 3.04 PE RVU, 0.04 MP RVU) multiplied by the 2025 conversion factor of 32.3465.

Does Medicare cover microvolt T-wave alternans testing?

Medicare coverage for CPT 93025 varies by jurisdiction and Local Coverage Determination (LCD). Many Medicare Administrative Contractors have non-coverage policies or limit coverage to specific indications such as patients with reduced ejection fraction being considered for ICD therapy. Verify your local LCD before performing the test and obtain an Advance Beneficiary Notice (ABN) if coverage is uncertain.

Can CPT 93025 be billed with a stress test on the same day?

CPT 93025 can potentially be billed with stress testing (93015-93018) on the same date if the services are distinct and separately documented, but you must append modifier 59 or XU to indicate a distinct procedural service. Documentation must clearly demonstrate that MTWA provided separate clinical information and was performed for a different purpose than the stress test. Many payers may consider these bundled without exceptional circumstances.

What diagnosis codes support medical necessity for CPT 93025?

Diagnosis codes supporting CPT 93025 typically include cardiomyopathy (I42.x), heart failure with reduced ejection fraction (I50.2x), old myocardial infarction (I25.2), ventricular arrhythmias (I47.2, I49.0x), and cardiac risk evaluation codes. The specific ICD-10 code must demonstrate structural heart disease or arrhythmia risk factors. Local Coverage Determinations may specify required diagnoses and clinical criteria such as LVEF ≤35-40%.

Who can interpret microvolt T-wave alternans tests?

CPT 93025 interpretation must be performed by a physician qualified in cardiovascular disease, typically a board-certified cardiologist or electrophysiologist. The interpreting physician must have training in MTWA methodology and cardiac electrophysiology. Technical staff may perform the test under physician supervision, but only a qualified physician can bill for the professional component (modifier 26) interpretation.

What is the difference between billing 93025 globally versus with modifiers 26 and TC?

Billing 93025 globally (without modifiers) means your practice provided both the technical component (equipment, staff, supplies) and professional component (physician interpretation) and receives the full $123.89 reimbursement. Using modifier 26 bills only physician interpretation (typically 40% of total), while modifier TC bills only the technical service (typically 60%). Hospitals bill TC when employed physicians bill 26 separately.

How often can CPT 93025 be billed for the same patient?

Frequency limitations for CPT 93025 vary by payer LCD, but most Medicare contractors consider MTWA a one-time or infrequent risk stratification tool rather than serial monitoring. Repeat testing typically requires documentation of significant clinical change such as new MI, worsening heart failure, change in ejection fraction, or indeterminate prior result with clinical need for clarification. Billing more frequently than annually often triggers medical necessity review.

Reimbursement estimates for informational purposes only. Verify with CMS and individual payers before billing decisions. Updated for 2025.